GRAIL reported Q4 2025 total revenue of USD 43.6 million (+14% YoY), including U.S. Galleri revenue of USD 41.3 million (+31% YoY). Q4 net loss was USD 99.2 million, which included USD 34.6 million of amortization of Illumina acquisition-related intangible items; gross loss was USD 11.1 million. Non-GAAP adjusted gross profit was USD 23.1 million (+29% YoY) and non-GAAP adjusted EBITDA was a loss of USD 71.8 million. For FY 2025, total revenue was USD 147.2 million (+17% YoY) and U.S. Galleri revenue was USD 136.8 million (+26% YoY), with more than 185,000 Galleri tests sold during 2025. FY net loss was USD 408.4 million, including USD 138.3 million of amortization of Illumina acquisition-related intangible items and a USD 28.0 million intangible assets impairment; gross loss was USD 62.6 million. Non-GAAP adjusted gross profit was USD 73.6 million (+27% YoY) and non-GAAP adjusted EBITDA was a loss of USD 320.6 million. Cash, cash equivalents and short-term marketable securities totaled USD 904.4 million at Dec. 31, 2025. Business updates included completion of Galleri’s PMA submission to the FDA in January, announcement of topline results from the 142,000-participant NHS-Galleri trial, and completion of analysis of the full 35,000-participant PATHFINDER 2 study. GRAIL also highlighted that the Medicare Multi-Cancer Early Detection Screening Coverage Act became federal law and said it expanded access via digital health platforms, including the launch of the Hims & Hers Multi-Cancer Test by Galleri.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191602PR_NEWS_USPR_____LA91810) on February 19, 2026, and is solely responsible for the information contained therein.